Cytokine Storm Syndromes Beyond COVID-19: Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, CAR-T Cell-Related Cytokine Release Syndrome, and Targeted Immunomodulation Strategies

Dr Neeraj Manikath , claude.ai

Abstract

Background: Cytokine storm syndromes represent a spectrum of hyperinflammatory conditions characterized by excessive immune activation leading to multi-organ dysfunction. While COVID-19 brought widespread attention to cytokine storms, several distinct syndromes including hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T cell-related cytokine release syndrome (CRS) present unique diagnostic and therapeutic challenges in critical care.

Objective: To provide a comprehensive review of non-COVID cytokine storm syndromes, focusing on pathophysiology, diagnostic approaches, and evidence-based management strategies with emphasis on targeted immunomodulation.

Methods: Systematic review of current literature, clinical guidelines, and expert consensus statements published between 2018-2024.

Results: Each syndrome demonstrates distinct pathophysiological mechanisms requiring tailored therapeutic approaches. Early recognition and prompt intervention with targeted immunomodulators significantly improve outcomes.

Conclusions: Understanding the nuanced differences between cytokine storm syndromes is crucial for critical care practitioners to optimize patient outcomes through precision medicine approaches.

Keywords: Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome, CAR-T therapy, immunomodulation, critical care

Introduction

The term "cytokine storm" has become ubiquitous in medical literature, particularly following the COVID-19 pandemic. However, this phenomenon encompasses a diverse group of hyperinflammatory syndromes that predate the current pandemic by decades. Critical care physicians must recognize that cytokine storm is not a single entity but rather a final common pathway of immune dysregulation manifesting through distinct clinical syndromes, each requiring specific diagnostic and therapeutic approaches.

The three major non-COVID cytokine storm syndromes encountered in critical care include hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and chimeric antigen receptor T-cell (CAR-T) therapy-related cytokine release syndrome (CRS). While these conditions share common features of excessive inflammatory cytokine production, their underlying pathophysiology, clinical presentation, and optimal management strategies differ significantly.

This review aims to provide critical care practitioners with a comprehensive understanding of these syndromes, emphasizing practical diagnostic approaches, evidence-based treatment strategies, and emerging targeted therapies that have revolutionized patient outcomes.

Pathophysiology: The Common Thread and Unique Mechanisms

Shared Pathways

All cytokine storm syndromes involve excessive activation of the innate and adaptive immune systems, leading to uncontrolled production of pro-inflammatory cytokines including interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and IL-10. This hyperinflammatory state results in:

Widespread endothelial dysfunction and increased vascular permeability
Coagulopathy with both thrombotic and hemorrhagic complications
Multi-organ dysfunction syndrome (MODS)
Hemodynamic instability resembling septic shock

Syndrome-Specific Mechanisms

Hemophagocytic Lymphohistiocytosis (HLH)

HLH represents a disorder of immune homeostasis characterized by defective cytotoxic function of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Primary HLH results from genetic mutations affecting perforin-mediated cytotoxicity, while secondary HLH occurs in the setting of infections, malignancies, or autoimmune conditions.

The inability to effectively eliminate activated macrophages and antigen-presenting cells leads to persistent immune stimulation and uncontrolled hemophagocytosis by activated macrophages. Key cytokines include IFN-γ, IL-18, and soluble IL-2 receptor (sCD25).

Macrophage Activation Syndrome (MAS)

MAS represents a severe complication of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease, though it can occur in other rheumatologic conditions. The pathophysiology involves excessive activation of macrophages and T-helper 1 cells, with particular elevation of IL-1β, IL-6, and IL-18.

Unlike HLH, MAS typically occurs in patients with underlying autoimmune conditions and may be triggered by infections, medications, or disease flares. The IL-1 pathway plays a particularly important role in MAS pathogenesis.

CAR-T Cell-Related Cytokine Release Syndrome (CRS)

CRS following CAR-T cell therapy results from massive T-cell activation and expansion following antigen engagement. This leads to release of inflammatory cytokines both directly from CAR-T cells and secondarily from activated macrophages and endothelial cells.

The syndrome typically occurs 1-14 days post-infusion, with severity correlating with tumor burden, CAR-T cell expansion, and peak serum cytokine levels. IL-6 serves as the primary driver of CRS, making it an ideal therapeutic target.

Clinical Presentation and Diagnostic Challenges

Hemophagocytic Lymphohistiocytosis

Clinical Pearls:

Think HLH in any critically ill patient with persistent fever, splenomegaly, and cytopenias
Neurological symptoms occur in 30-40% of cases and may be the presenting feature
Hepatomegaly is more common than splenomegaly in adults

Diagnostic Criteria (HLH-2004):

Five of the following eight criteria:

Fever ≥38.5°C
Splenomegaly
Cytopenias (≥2 lineages): Hemoglobin <90 g/L, platelets <100×10⁹/L, neutrophils <1.0×10⁹/L
Hypertriglyceridemia (≥3.0 mmol/L) and/or hypofibrinogenemia (≤1.5 g/L)
Hemophagocytosis in bone marrow, spleen, or lymph nodes
Low or absent NK cell activity
Ferritin ≥500 μg/L
Soluble CD25 ≥2,400 U/mL

Critical Care Hack: Don't wait for bone marrow biopsy to show hemophagocytosis - it's present in only 60% of cases at diagnosis. Focus on the combination of ferritin >10,000 μg/L, sCD25 elevation, and clinical picture.

Macrophage Activation Syndrome

Clinical Pearls:

MAS should be suspected in any patient with known rheumatologic disease who develops acute deterioration with fever and cytopenias
Unlike typical disease flares, joint symptoms may paradoxically improve during MAS
Hepatic dysfunction is more prominent than in HLH

Diagnostic Criteria (2016 Classification):

Febrile patient with known or suspected sJIA
Ferritin ≥684 ng/mL
Plus any two of:
- Platelets ≤181×10⁹/L
- AST >48 U/L
- Triglycerides >156 mg/dL
- Fibrinogen ≤360 mg/dL

Oyster: Ferritin levels in MAS are typically lower than in HLH (often 1,000-10,000 μg/L vs >10,000 μg/L in HLH), but the clinical significance remains high.

CAR-T Cell-Related CRS

Clinical Pearls:

CRS severity correlates with peak IL-6 levels and CAR-T cell expansion
Constitutional symptoms (fever, fatigue) precede hemodynamic instability
Neurological toxicity (ICANS - Immune Cell-Associated Neurotoxicity Syndrome) can occur concurrently but represents a distinct entity

Grading System (ASTCT Consensus):

Grade 1: Fever with or without constitutional symptoms Grade 2: Grade 1 plus hypotension not requiring vasopressors and/or hypoxia requiring low-flow nasal cannula Grade 3: Grade 2 plus hypotension requiring vasopressors and/or hypoxia requiring high-flow nasal cannula, face mask, non-rebreather mask, or Venturi mask Grade 4: Grade 3 plus life-threatening symptoms including requirement for positive pressure ventilation

Critical Care Hack: Trend IL-6 levels every 12 hours during the first 72 hours post-CAR-T infusion. Rising levels predict severe CRS before clinical deterioration.

Diagnostic Workup and Monitoring

Laboratory Investigations

Initial Assessment:

Complete blood count with differential
Comprehensive metabolic panel including liver function tests
Coagulation studies (PT, aPTT, fibrinogen, D-dimer)
Inflammatory markers (ESR, CRP, procalcitonin)
Ferritin and lactate dehydrogenase
Triglycerides and soluble CD25 (if available)
Blood cultures and infectious workup

Syndrome-Specific Testing:

For HLH:

NK cell function assay
Genetic testing for familial HLH mutations (especially in young patients)
Flow cytometry for perforin, granzyme expression
Soluble CD25 (sIL-2R)

For MAS:

IL-18 and IL-1β levels (research settings)
Underlying rheumatologic disease activity markers
Complement levels (C3, C4)

For CAR-T CRS:

IL-6, IL-10, IFN-γ levels
CAR-T cell expansion markers (flow cytometry)
Cardiac biomarkers (troponin, BNP)

Imaging Studies:

Chest CT for pulmonary edema, effusions
Abdominal imaging for hepatosplenomegaly
Echocardiography for cardiac function assessment
Brain MRI if neurological symptoms present

Monitoring Parameters in Critical Care

Hemodynamic Monitoring:

Arterial blood pressure monitoring
Central venous pressure assessment
Cardiac output measurement (if indicated)
Fluid balance and urine output

Respiratory Monitoring:

Arterial blood gas analysis
Chest imaging for ARDS development
Mechanical ventilation parameters if intubated

Laboratory Trending:

Daily CBC, comprehensive metabolic panel, coagulation studies
Ferritin and LDH every 2-3 days
Cytokine levels (if available) for CAR-T patients

Treatment Strategies and Targeted Immunomodulation

General Supportive Care

Hemodynamic Support:

Early fluid resuscitation with balanced crystalloids
Vasopressor support (norepinephrine first-line)
Consideration of corticosteroids for refractory shock

Respiratory Support:

Lung-protective ventilation strategies if ARDS develops
Early prone positioning for severe ARDS
ECMO consideration for refractory respiratory failure

Hematologic Support:

Platelet transfusion for bleeding or invasive procedures (goal >20,000/μL)
Red blood cell transfusion for symptomatic anemia
Fresh frozen plasma for significant coagulopathy

Targeted Immunomodulation

Hemophagocytic Lymphohistiocytosis

First-Line Therapy: HLH-94 Protocol

Dexamethasone 10 mg/m² daily for 2 weeks, then taper
Etoposide 150 mg/m² twice weekly for 2 weeks, then weekly
Consider cyclosporine A 3-5 mg/kg daily (especially for CNS involvement)

Alternative Regimens:

Alemtuzumab: 10 mg IV daily for 5 days (for refractory cases)
Anakinra: 1-2 mg/kg daily (IL-1 receptor antagonist)
Tocilizumab: 8 mg/kg (maximum 800 mg) every 2 weeks (anti-IL-6 receptor)

Critical Care Hack: In critically ill patients, consider starting with high-dose methylprednisolone (1-2 mg/kg daily) instead of dexamethasone for immediate anti-inflammatory effect, then transition to protocol-based therapy.

Novel Therapies:

Emapalumab: Anti-IFN-γ monoclonal antibody, FDA-approved for refractory primary HLH
JAK inhibitors: Ruxolitinib showing promise in case series

Macrophage Activation Syndrome

First-Line Therapy:

High-dose corticosteroids: Methylprednisolone 10-30 mg/kg daily for 3 days, then 2-4 mg/kg daily
Anakinra: 1-2 mg/kg daily subcutaneously (can increase to 4-8 mg/kg daily in severe cases)

Second-Line Options:

Tocilizumab: 8 mg/kg IV (particularly effective if IL-6 levels elevated)
Cyclosporine A: 2-5 mg/kg daily divided BID
Canakinumab: 4 mg/kg (maximum 300 mg) subcutaneously

Oyster: Unlike HLH, etoposide is generally avoided in MAS due to increased infection risk in rheumatologic patients already on immunosuppression.

Refractory Cases:

Plasma exchange (for severe cases with multi-organ failure)
IVIG 2 g/kg over 2-5 days
Rituximab 375 mg/m² weekly for 4 doses (if EBV-associated)

CAR-T Cell-Related CRS

Grade 1 CRS:

Supportive care
Acetaminophen and NSAIDs for symptom management
Monitor closely for progression

Grade 2 CRS:

Tocilizumab: 8 mg/kg IV (maximum 800 mg), may repeat after 8 hours if no improvement
Supportive care with supplemental oxygen and IV fluids
Consider corticosteroids if no response to tocilizumab

Grade 3-4 CRS:

Tocilizumab: 8 mg/kg IV, may repeat every 8 hours for up to 4 doses
Corticosteroids: Methylprednisolone 1-2 mg/kg daily (use sparingly as may impair CAR-T cell efficacy)
Intensive care management with vasopressor and ventilatory support

Critical Care Hack: Give tocilizumab early in Grade 2 CRS - waiting for Grade 3-4 leads to prolonged recovery and worse outcomes.

Novel Approaches:

Siltuximab: Alternative anti-IL-6 agent if tocilizumab unavailable
Anakinra: May be effective for refractory cases
Dasatinib: Tyrosine kinase inhibitor showing promise for severe CRS

Monitoring Treatment Response

Clinical Indicators:

Defervescence within 24-48 hours
Hemodynamic stabilization
Improvement in organ function
Resolution of cytopenias

Laboratory Markers:

Declining ferritin levels (>50% reduction by day 7)
Normalization of triglycerides and fibrinogen
Decreasing inflammatory markers (CRP, ESR)
Rising platelet count and neutrophil count

Complications and Long-term Outcomes

Acute Complications

Cardiovascular:

Cardiomyopathy and heart failure
Arrhythmias
Pericardial effusion

Pulmonary:

ARDS
Pulmonary hemorrhage
Secondary infections

Neurological:

Encephalopathy
Seizures
Posterior reversible encephalopathy syndrome (PRES)
Central nervous system hemorrhage

Hematologic:

Disseminated intravascular coagulation (DIC)
Thrombotic microangiopathy
Severe bleeding complications

Long-term Sequelae

HLH Survivors:

Neurological deficits (10-20% of survivors)
Chronic liver dysfunction
Growth retardation in children
Risk of malignancy development

MAS Survivors:

Joint damage from underlying rheumatologic disease
Chronic kidney disease
Liver fibrosis (rare)

CAR-T CRS Survivors:

Generally excellent long-term outcomes if acute phase survived
Potential for late B-cell aplasia requiring immunoglobulin replacement
Monitoring for secondary malignancies

Special Populations and Considerations

Pediatric Patients

Key Differences:

Higher incidence of primary HLH due to genetic mutations
Different normal values for laboratory parameters
Weight-based dosing considerations for medications
Greater risk of long-term growth and developmental effects

Oyster: Ferritin levels >10,000 μg/L in children are more specific for HLH than in adults, where similar levels can be seen with other conditions.

Pregnant Patients

Unique Considerations:

Pregnancy can trigger HLH or MAS in susceptible individuals
Limited safety data for many targeted therapies
Multidisciplinary approach with maternal-fetal medicine essential
Corticosteroids and IVIG generally considered safer options

Malignancy-Associated Cases

Special Challenges:

Difficulty distinguishing from tumor lysis syndrome
Concurrent chemotherapy effects on laboratory values
Immunocompromised state increasing infection risk
Potential for hemophagocytosis due to underlying hematologic malignancy

Emerging Therapies and Future Directions

Novel Therapeutic Targets

IL-18 Pathway:

Tadekinig alfa (recombinant IL-18 binding protein) in clinical trials for MAS
Promising results in pediatric studies

Complement System:

Eculizumab (anti-C5) showing efficacy in case reports
Potential role in thrombotic microangiopathy component

Cytokine Adsorption:

CytoSorb hemoadsorption showing promise in small studies
May reduce cytokine burden while preserving cellular immunity

Precision Medicine Approaches

Biomarker-Guided Therapy:

IL-6 levels guiding tocilizumab dosing in CAR-T CRS
Ferritin kinetics predicting treatment response
Genetic profiling for personalized HLH therapy

Pharmacokinetic Optimization:

Therapeutic drug monitoring for cyclosporine and anakinra
Population pharmacokinetic models for optimal dosing

Practical Clinical Pearls and Hacks

Diagnostic Pearls

The "3 F's" of cytokine storm: Fever, Ferritin ↑, and Falling cell counts
Ferritin trajectory matters more than absolute value: Doubling in 24-48 hours suggests active process
Think cytokine storm if: Patient has "sepsis" but cultures remain negative and antibiotics aren't helping
Triglycerides >400 mg/dL in a febrile patient: Consider HLH even without other classic features

Treatment Hacks

Start treatment based on clinical suspicion: Don't wait for all diagnostic criteria to be met
Steroid dosing: Use methylprednisolone pulse (15-30 mg/kg) for rapid effect in fulminant cases
Tocilizumab timing: Give before patient requires high-dose vasopressors for best outcomes
Anakinra loading: Consider 4 mg/kg daily for first 3 days, then reduce to 2 mg/kg
Monitor response at 48-72 hours: If no improvement, escalate therapy rather than continuing same regimen

ICU Management Pearls

Fluid management: Liberal early, restrictive once cytokine levels controlled
Nutrition: High protein needs due to hypercatabolism, consider early enteral nutrition
DVT prophylaxis: Essential but monitor closely for bleeding due to coagulopathy
Infection screening: High index of suspicion as fever may persist despite antimicrobials
Neurological monitoring: Daily neuro checks; consider MRI for persistent altered mental status

Prognosis and Outcome Prediction

Prognostic Factors

Poor Prognostic Indicators:

Age >60 years (HLH)
CNS involvement
Ferritin >50,000 μg/L
Multi-organ failure at presentation
Delayed diagnosis and treatment initiation

Good Prognostic Factors:

Early recognition and treatment
Absence of neurological symptoms
Underlying trigger identifiable and treatable
Rapid response to initial therapy

Scoring Systems

HLH Probability Calculator (HScore):

Uses clinical and laboratory variables
Score >169 suggests 93% probability of HLH
Useful for early identification in uncertain cases

CAR-T CRS Risk Stratification:

High tumor burden
Elevated baseline LDH and ferritin
Presence of extramedullary disease

Quality Improvement and Systems Approaches

Early Recognition Systems

Alert Systems:

EMR alerts for ferritin >1,000 μg/L with fever
Automatic consultation triggers for hematology-oncology
Nursing education on early warning signs

Multidisciplinary Teams:

Rheumatology for MAS cases
Hematology-oncology for HLH and CAR-T CRS
Critical care for hemodynamic management
Pharmacy for drug dosing and monitoring

Standardized Care Pathways

Order Sets:

Diagnostic laboratory bundles
Treatment protocols with decision trees
Monitoring parameters and schedules

Quality Metrics:

Time to diagnosis
Time to treatment initiation
ICU length of stay
30-day mortality rates

Conclusions

Cytokine storm syndromes beyond COVID-19 represent a complex group of hyperinflammatory conditions requiring sophisticated diagnostic acumen and targeted therapeutic interventions. Success in managing these conditions depends on early recognition, prompt initiation of appropriate immunosuppression, and meticulous supportive care.

The advent of targeted biologics has revolutionized treatment outcomes, with tocilizumab for CAR-T CRS, anakinra for MAS, and emapalumab for refractory HLH representing major therapeutic advances. However, these conditions remain challenging, with mortality rates ranging from 10-50% depending on syndrome severity and timing of intervention.

Future research directions should focus on:

Development of rapid diagnostic biomarkers
Personalized treatment algorithms based on cytokine profiles
Novel therapeutic targets beyond current cytokine inhibitors
Long-term outcome studies to guide survivorship care

Critical care physicians must maintain high clinical suspicion for these syndromes, understand their unique pathophysiological mechanisms, and be prepared to initiate targeted therapy promptly. The paradigm has shifted from "supportive care only" to "early aggressive immunomodulation," fundamentally changing outcomes for these critically ill patients.

As our understanding of immune dysregulation continues to evolve, the ability to precisely diagnose and treat cytokine storm syndromes will undoubtedly improve, offering hope for even better outcomes in these challenging conditions.

References

La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477.
Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome complicating systemic juvenile idiopathic arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;75(3):481-489.
Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.
Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285-295.
Schultz KR, Alonzo TA, Slayton WB, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175-5181.
Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor: a double-blind, randomized controlled trial. Nat Med. 2021;27(10):1752-1760.
Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811-1822.
Khadka S, Gajurel BP, Kadel B, et al. Cytokine release syndrome: Current perspectives. Immun Inflamm Dis. 2022;10(4):e597.
Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45-55.
Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.
Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020;72(7):1059-1063.
Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259-268.
Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6(6):664-679.

Monday, September 15, 2025